Andrew R. Boll
2013
In 2013, Andrew R. Boll earned a total compensation of $652.5K as Chief Financial Officer at Imprimis Pharmaceuticals, a 427% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $46,500 |
|---|---|
| Option Awards | $467,298 |
| Salary | $138,750 |
| Total | $652,548 |
Boll received $467.3K in option awards, accounting for 72% of the total pay in 2013.
Boll also received $46.5K in non-equity incentive plan and $138.8K in salary.
Rankings
In 2013, Andrew R. Boll's compensation ranked 8,422nd out of 12,286 executives tracked by ExecPay. In other words, Boll earned more than 31.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,422 out of 12,286 | 32nd |
Division Manufacturing | 3,063 out of 4,612 | 34th |
Major group Chemicals And Allied Products | 960 out of 1,462 | 34th |
Industry group Drugs | 729 out of 1,156 | 37th |
Industry Pharmaceutical Preparations | 578 out of 890 | 35th |
Source: SEC filing on April 10, 2015.
Boll's colleagues
We found one more compensation record of an executive who worked with Andrew R. Boll at Imprimis Pharmaceuticals in 2013.
2013
Mark Baum
Imprimis Pharmaceuticals
Chief Executive Officer
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019